CCA
HRMY icon

Catalyst Capital Advisors’s Harmony Biosciences HRMY Stock Holding History

Catalyst Capital Advisors’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-560
Closed -$27K – 365
2022
Q1 		$27K Buy
+560
New +$22.8K ﹤0.01% 361

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Catalyst Capital Advisors's HRMY Position: Q2 2022 in Review

Catalyst Capital Advisors sold out of Harmony Biosciences (HRMY) in Q2 2022, closing a stake of 560 shares — an estimated $27K sold.

Catalyst Capital Advisors first reported a position in HRMY in Q1 2022 and held it in 1 quarter. The position peaked at $27K in Q1 2022. 183 funds tracked by Wall St. Rank hold HRMY as of Q2 2022.

  • Catalyst Capital Advisors reported no remaining Harmony Biosciences position as of Q2 2022 after selling out during the quarter.
  • Catalyst Capital Advisors sold 560 Harmony Biosciences shares in Q2 2022, an estimated $27K.
  • Catalyst Capital Advisors first reported a position in Harmony Biosciences in Q1 2022 and held it in 1 quarter.
  • Catalyst Capital Advisors's Harmony Biosciences position peaked at $27K in Q1 2022.
  • 183 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2022.

Based on Catalyst Capital Advisors's 13F filing for Q2 2022, filed 9 Aug 2022.